DREAMM-7 phase III trial shows Blenrep combination nearly tripled median progression-free survival versus standard of care combination in patients with relapsed/refractory multiple myeloma
DREAMM-7 phase III trial shows Blenrep combination nearly tripled median progression-free survival versus standard of care combination in patients with relapsed/refractory multiple myeloma
Provider: View Press Release Type: Link Title: DREAMM-7 phase III trial shows Blenrep combination nearly tripled median progression-free survival versus standard of care combination in patients with relapsed/refractory multiple myeloma | GSK Description: Results from an interim analysis of the DREAMM-7 phase III head-to-head trial.
GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency for the prevention of RSV disease in adults aged 50-59 at increased risk
GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency for the prevention of RSV disease in adults aged 50-59 at increased risk
Provider: View Press Release Type: Link Title: GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency for the prevention of RSV disease in adults aged 50-59 at increased risk | GSK Description: Application supported by positive results of a Phase III study showing immune response and acceptable tolerability profile.
European Commission authorises GSK’s Omjjara (momelotinib)
Provider: View Press Release Type: Link Title: European Commission authorises GSK’s Omjjara (momelotinib) | GSK Description: First medicine in the EU specifically indicated for splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia
Nucala (mepolizumab) approved in China for use in severe asthma with an eosinophilic phenotype
Provider: View Press Release Type: Link Title: Nucala (mepolizumab) approved in China for use in severe asthma with an eosinophilic phenotype | GSK Description: Mepolizumab is the first targeted IL-5 biologic available in China as an add-on maintenance treatment for severe eosinophilic asthma.
